drugset / Trial / NCT01980329

Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites

NCT01980329

Phase 1 Completed 24 enrolled Johns Hopkins University
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the influence of genetic polymorphism of cytochrome P450 3A5 on pharmacokinetics of maraviroc and its oxidative metabolites

Timeline

Start
2013-01
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Maraviroc Other / unclassified 300 mg Oral

Indications